RxDoctor Payments Data

Kurt Olinde, MD

Cardiovascular Disease · Monroe, LANPI 1528170255

Payments from drug & device makers

$1,032in general payments, 2019–2025

Across 55 payments — averaging $18.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$149
  • Novartis$126
  • Lexicon Pharmaceuticals, Inc.$114
  • Bayer$99
  • Inspire Medical Systems, Inc.$98
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$55
  • plus $391 from 13 others

What the payments were for

  • Food & beverage$1,01298%
  • Education$202%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,032 in reported general payments places this provider in the 30th percentile of 281 cardiovascular disease providers in Louisiana.

See all cardiovascular disease providers in Louisiana

Medicare billing

Part B allowed, 2024
$48,708
Medicare patients
170
Services billed
606

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban115$82,059
MounjaroTirzepatide63$71,810
EntrestoSacubitril/Valsartan85$56,256
JardianceEmpagliflozin65$45,639
OzempicSemaglutide35$35,365
MultaqDronedarone Hcl20$21,931
Repatha SureclickEvolocumab32$20,349
TrulicityDulaglutide13$12,615
Metoprolol Succinate353$8,897
JanuviaSitagliptin Phosphate12$5,081
Ezetimibe158$4,977
Pravastatin Sodium235$4,798
Valsartan140$4,388
Rosuvastatin Calcium225$4,311
Dexlansoprazole DrDexlansoprazole21$2,894

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$53$84,42576 claims
PfizerEliquis$40$82,059115 claims
NovartisEntresto$126$56,25685 claims
Novo NordiskOzempic$29$35,36535 claims
MerckJanuvia$41$5,08112 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 281 cardiovascular disease providers in Louisiana.

Other cardiovascular disease in Monroe

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →